首页 | 本学科首页   官方微博 | 高级检索  
     


Detection of Staphylococcus aureus delta-toxin production by whole-cell MALDI-TOF mass spectrometry
Authors:Julie Gagnaire  Olivier Dauwalder  Sandrine Boisset  David Khau  Anne-Marie Freydière  Florence Ader  Michèle Bes  Gerard Lina  Anne Tristan  Marie-Elisabeth Reverdy  Adrienne Marchand  Thomas Geissmann  Yvonne Benito  Géraldine Durand  Jean-Philippe Charrier  Jerome Etienne  Martin Welker  Alex Van Belkum  François Vandenesch
Affiliation:Hospices Civils de Lyon, Centre National de Référence des Staphylocoques, Centre de Biologie et de Pathologie Est, Bron, France.
Abstract:The aim of the present study was to detect the Staphylococcus aureus delta-toxin using Whole-Cell (WC) Matrix Assisted Laser Desorption Ionization-Time-of-Flight (MALDI-TOF) mass spectrometry (MS), correlate delta-toxin expression with accessory gene regulator (agr) status, and assess the prevalence of agr deficiency in clinical isolates with and without resistance to methicillin and glycopeptides. The position of the delta-toxin peak in the mass spectrum was identified using purified delta-toxin and isogenic wild type and mutant strains for agr-rnaIII, which encodes delta-toxin. Correlation between delta-toxin production and agr RNAIII expression was assessed by northern blotting. A series of 168 consecutive clinical isolates and 23 unrelated glycopeptide-intermediate S. aureus strains (GISA/heterogeneous GISA) were then tested by WC-MALDI-TOF MS. The delta-toxin peak was detected at 3005±5 Thomson, as expected for the naturally formylated delta toxin, or at 3035±5 Thomson for its G10S variant. Multivariate analysis showed that chronicity of S. aureus infection and glycopeptide resistance were significantly associated with delta-toxin deficiency (p?=?0.048; CI 95%: 1.01-10.24; p?=?0.023; CI 95%: 1.20-12.76, respectively). In conclusion, the S. aureus delta-toxin was identified in the WC-MALDI-TOF MS spectrum generated during routine identification procedures. Consequently, agr status can potentially predict infectious complications and rationalise application of novel virulence factor-based therapies.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号